Insulin head-to-head shows little difference

Both showed relatively low hypoglycaemia risk

A head-to-head study of two second-generation basal insulin analogues shows they are comparable for treating uncontrolled type 2 diabetes, researchers say.


Dr Julio Rosenstock of Dallas Diabetes Research Center at Medical City in Texas and colleagues conducted a 24-week multicenter, open-label, parallel-group non-inferiority study that included 466 patients randomized to evening dosing with glargine 300 units/mL (Sanofi)  and 463 patients to degludec (Novo Nordsk) 100 units/mL.

The drugs were titrated to achieve fasting self-monitored plasma glucose